Introduction {#Sec1}
============

The worldwide prevalence of diabetes mellitus (DM) in adults was estimated to be 8.4% in 2017 and was predicted to rise to 9.9% in 2045 \[[@CR1]\], which is similar to the estimated rise in prevalence in Japan (7.7% in 2017 to 8.3% in 2045) \[[@CR2]\]. The primary goal of diabetes treatment is to achieve optimal glycemic control \[[@CR3]\]. Glycemic control is currently assessed using the most common marker, glycated hemoglobin A1c (HbA1c), which closely correlates with the average plasma glucose level over a preceding 8- to 12-week period \[[@CR4]\], as well as fasting blood glucose in a clinical setting. Although HbA1c provides a reliable measure of long-term glycemic control and chronic hyperglycemia \[[@CR5]\], there is evidence to suggest that glycemic variability (GV) may contribute independently to diabetes-related complications \[[@CR3], [@CR6]--[@CR9]\]. GV measured by standard deviation (SD) reflects blood glucose oscillations that occur throughout the day, including hypoglycemic and postprandial increases, and variability between daily means that are unlikely to be captured by HbA1c or fasting blood glucose measurements \[[@CR3], [@CR10]\].

Evidence from some studies suggests that, similar to chronic hyperglycemia \[[@CR11]\], long-term high GV may increase the risk of microvascular and macrovascular complications associated with type 2 DM (T2DM) \[[@CR8], [@CR9]\], while severe hypoglycemia is associated with increased mortality \[[@CR6], [@CR7]\]. Although the precise mechanism by which GV may adversely affect cardiovascular risk is not fully understood, some evidence suggests that acute GV increases oxidative stress \[[@CR12]\] and endothelial dysfunction \[[@CR13]\], both of which may contribute to the development of cardiovascular complications. GV has also been strongly associated with increased incidence of hypoglycemia \[[@CR10]\], as well as contributing to increased mean blood glucose values \[[@CR3]\].

Dipeptidyl peptidase 4 (DPP4) inhibitors are antidiabetic agents that bind to the enzyme DPP4 to inhibit the degradation of the incretins, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), both of which play key roles in glucose homeostasis and glycemic control \[[@CR14]\]. By prolonging the activity of endogenous GLP-1 and GIP, DPP4 inhibitors can improve postprandial hyperglycemia, without inducing hypoglycemia, in patients with T2DM \[[@CR15]\]. Trelagliptin is an oral antidiabetic medication that inhibits DPP4 and improves glycemic control in patients with diabetes \[[@CR16]\]. Unlike early DPP4 inhibitors, which are administered once or twice daily, trelagliptin is administered once weekly \[[@CR17]\]. However, despite the less frequent dosing, a phase 3 clinical study in patients with T2DM demonstrated that the efficacy of once-weekly trelagliptin was non-inferior to that of once-daily alogliptin in lowering HbA1c \[[@CR18]\]. Although various oral hypoglycemic agents have been evaluated in Japan using the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents \[[@CR19]\], the effects of these agents, including alogliptin and trelagliptin, on GV have not been investigated. Therefore, the present exploratory pilot study was undertaken to investigate the effect of trelagliptin 100 mg once weekly and alogliptin 25 mg once daily on GV in patients with T2DM.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a randomized, open-label, parallel-group, exploratory study that evaluated the effect of trelagliptin 100 mg administered once weekly or alogliptin 25 mg administered once daily for 4 weeks. GV was assessed in patients with T2DM using continuous glucose monitoring (CGM) (Fig. [1](#Fig1){ref-type="fig"}). An assigned person generated the allocation list. Allocation was conducted at the enrollment center using a web case enrollment system on day 1. Eligible patients were randomized 1:1 using the allocation list to receive either trelagliptin 100 mg or alogliptin 25 mg, stratified by baseline HbA1c (less than 7.5% or at least 7.5%) and age (less than 65 or at least 65 years). Randomization was preceded by a 2-day observation period, followed by a 29-day treatment period. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study protocol, informed consent form, and other regulation-specified documents were reviewed and approved by the Independent Ethics Committees at Nakakinen Clinic. The study was conducted between June 2016 and April 2017 at two study sites (medical institutions) in Japan, and is registered at ClinicalTrials.gov (NCT02771093) and JAPIC (JapicCTI-163250). The study was registered on May 11, 2016.Fig. 1Study design. CGM continuous glucose monitoring

Participants {#Sec4}
------------

Patient eligibility criteria included patients aged at least 20 years old with T2DM, HbA1c (National Glycohemoglobin Standardization Program value) of at least 6.5% and less than 8.5%, and stable glycemic control with at most 1% change in HbA1c at the start of the observation period \[day − 2 (visit 1)\] vs the preceding 6 weeks. Patients must have been receiving stable diet and exercise therapy (if required) for at least 4 weeks before the start of the observation period (day − 2). Key exclusion criteria included patients who were receiving antidiabetic medications within 4 weeks of the start of the observation period, or patients who changed (including discontinuation or interruption) 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors or received new HMG-CoA reductase inhibitors within 4 weeks before the start of the observation period. Concomitant use of medications that may affect efficacy evaluation was prohibited throughout the duration of the study; these included antidiabetic medications other than the allocated study drugs, systemic glucocorticoids (excluding local/topical preparations), estrogen preparations, HMG-CoA reductase inhibitors other than those used at the time of informed consent, and acetaminophen.

During CGM, patients presented photographs of their meals to allow the investigator to monitor patient compliance to diet therapy.

CGM {#Sec5}
---

CGM was conducted using Medtronic iPro^®^2 (Medtronic MiniMed, Inc. Northridge, CA, USA), and was performed for 2 days during the observation period and 9 days (day 21--29) during the treatment period (Fig. [1](#Fig1){ref-type="fig"}). Patients calibrated their CGM during the observation and treatment periods by measuring their daily blood glucose levels at a minimum of three time points on the first day of the CGM (at least 2 h after the recorder was connected, 2 h after the first measurement, and at bedtime) and at four time points from the second day onward (before breakfast, before lunch, before the evening meal, and at bedtime).

Study Endpoints and Assessments {#Sec6}
-------------------------------

The primary endpoint was change from baseline (4 h before breakfast to 20 h post-breakfast on day − 1) in the SD of 24-h blood glucose values (mg/dL) measured each day from day 22 to 28 of the treatment period. Secondary efficacy endpoints included change from baseline in 24-h mean blood glucose on each day during day 22--28 of the treatment period; area under the glucose concentration--time curve (AUC) during periods when blood glucose was at least 180 mg/dL; change in 3-h postprandial blood glucose over time, 3 h after breakfast, lunch, and evening meal; change in AUC over time during periods when blood glucose levels were less than 70 mg/dL; changes in mean amplitude glycemic excursions (MAGE) from baseline; change from baseline in mean 24-h, daytime, and nocturnal blood glucose by visit; and AUC of blood glucose and change from baseline by visit.

Additional efficacy endpoints included change from baseline (day − 2) in plasma DPP4 activity; plasma DPP4 inhibition rate; change from baseline in glycoalbumin; change from baseline in 1,5-anhydroglucitol (AG); fasting blood glucose; fasting glucagon; fasting GLP-1; and fasting GIP at visit 3 and visit 5 of the 9-day CGM period (day 1 and day 29 of the treatment period).

The safety endpoints were the frequency and nature of treatment-emergent adverse events (TEAEs) over the 29-day treatment period.

Statistical Analyses {#Sec7}
--------------------

The planned sample size of 30 patients was determined with consideration of the feasibility of performing CGM in numerous patients, and was not based on a statistical power calculation.

The full analysis set (FAS), which was defined as all patients who were randomized and received at least one dose of the study drug, was used for the efficacy analyses unless otherwise specified. The safety analysis set included all patients who received at least one dose of the study drug.

For efficacy endpoints, summary statistics, including point-estimate and two-sided 95% confidence interval (CI) for the mean for each group, were calculated. Mean change (95% CI) of SD of 24-h blood glucose from baseline each day from day 22 to 28 (vs the start of the observation period) were calculated to evaluate changes in the SD of 24-h blood glucose values.

A TEAE was defined as an adverse event (AE) with a date of onset on or after the first dose of the study drug. AEs were coded using the Japanese version of the Medical Dictionary for Regulatory Activities, version 20.0, and displayed using System Organ Class and Preferred Term.

Results {#Sec8}
=======

A total of 27 patients signed the informed consent form, met the eligibility criteria for randomization (*n* = 13, once-weekly trelagliptin 100 mg; *n* = 14, once-daily alogliptin 25 mg), and completed the study treatment (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Schematic representation of patient disposition

The baseline demographics and patient characteristics are described in Table [1](#Tab1){ref-type="table"}. A total of 53.8% and 71.4% of patients in the trelagliptin group and alogliptin group were male, respectively. The mean duration of T2DM was 5.62 years and 6.15 years in the trelagliptin group and alogliptin group, respectively.Table 1Baseline characteristics of the randomized populationCharacteristicTrelagliptin 100 mg (*n* = 13)Alogliptin 25 mg (*n* = 14)Age, years, mean (SD)62.8 (10.14)62.7 (7.64)Male, *n* (%)7 (53.8)10 (71.4)Height, cm, mean (SD)160.9 (10.40)164.4 (7.17)Weight, kg, mean (SD)66.45 (14.11)64.15 (9.59)BMI, kg/m^2^, mean (SD)25.45 (2.95)23.65 (2.40)Duration of DM, years, mean (SD)5.62 (4.47)6.15 (4.68)HbA1c (NGSP), %, mean (SD)7.29 (0.62)7.19 (0.34)*BMI* body-mass index, *DM* diabetes mellitus, *HbA1c* glycated hemoglobin A1c, *NGSP* National Glycohemoglobin Standardization Program, *SD* standard deviation

All patients in both treatment groups fully complied (at least 75%) with the study medication.

Mean SD of 24-h Blood Glucose (Primary Efficacy Endpoint) {#Sec9}
---------------------------------------------------------

Mean SD (observed value) of 24-h blood glucose at baseline was 38.18 in the trelagliptin group and 40.44 in the alogliptin group. In the trelagliptin group, the mean SD (observed values) was 30.68 on day 22 and 30.84 on day 28. In the alogliptin group, mean SD (observed values) was 27.41 on day 22 and 28.81 on day 28.

Figure [3](#Fig3){ref-type="fig"} shows the mean change from baseline in the SD of 24-h blood glucose at day 22 and day 28, which was − 7.51 (95% CI − 17.10, 2.08) and − 7.35 (95% CI − 15.13, 0.44), respectively, in the trelagliptin group, and − 13.04 (95% CI − 20.84, − 5.23) and − 11.63 (95% CI − 18.67, − 4.59), respectively, in the alogliptin group.Fig. 3Change from baseline of SD of 24-h blood glucose. SD standard deviation

Secondary Efficacy Endpoints {#Sec10}
----------------------------

Changes from baseline for secondary efficacy endpoints are shown in Table [2](#Tab2){ref-type="table"}. The observed values for all secondary efficacy glycemic parameters at day 22 and day 28 numerically decreased from baseline in both groups, with the exception of mean nocturnal blood glucose, which increased from baseline at day 28 in the trelagliptin group. Of note, mean AUC over time at blood glucose less than 70 mg/dL (hypoglycemia) at baseline was 43.0 mg/dL min in the trelagliptin group and 0.0 mg/dL min in the alogliptin group. Mean change of AUC from baseline was − 31.2 mg/dL min (95% CI − 105.8, 43.3) in the trelagliptin group and + 0.4 mg/dL min in the alogliptin group at day 22, and − 43.0 mg/dL min (95% CI − 136.3, 50.3) in the trelagliptin group and 0.0 mg/dL min in the alogliptin group at day 28.Table 2Secondary efficacy endpoints: mean observed value and mean change from baseline in glycemic parametersTrelagliptin 100 mgAlogliptin 25 mgBaselineDay 22Change from baselineDay 28Change from baselineBaselineDay 22Change from baselineDay 28Change from baselinePost-prandial AUC over time when blood glucose ≥ 180 mg/dL is observed, mg/dL min2149.5 (640.7, 3658.4)1159.6 (68.2, 2251.0)− 989.9 (− 2508.3, 528.4)982.7 (343.1, 1622.3)− 1166.8 (− 2536.5, 202.8)3248.0 (1853.6, 4642.4)1000.1 (304.8, 1695.4)− 2247.9 (− 3524.3, − 971.6)1238.2 (358.8, 2117.7)− 2009.8 (− 3116.4, − 903.2) During the 3-h time period after breakfast557 (158.3, 955.7)466.3 (24.0, 908.6)− 90.7 (− 559.9, 378.5)342.2 (82.3, 602.0)− 214.8 (− 639.5, 209.8)1001.1 (513.1, 1489.1)341.1 (62.1, 620.0)− 660.1 (− 1128.5, − 191.6)397.5 (81.7, 713.3)− 603.6 (− 1005.5, − 201.8) During the 3-h time period after lunch520.1 (− 7.4, 1047.5)219.8 (− 5.6, 445.1)− 300.3 (− 924.2, 323.6)286.1 (37.6, 534.5)− 234.0 (− 767.7, 299.7)721.3 (218.8, 1223.8)94.7 (1.6, 187.8)− 626.6 (− 1126.4, − 126.7)174.9 (7.6, 342.1)− 546.4 (− 1085.4, − 7.4) During the 3-h time period after evening meal802.5 (165.3, 1439.8)294.9 (− 4.4, 594.3)− 507.6 (− 1077.9, 62.7)247.2 (− 54.4, 548.7)− 555.4 (− 1128.7, 17.9)696.6 (132.2, 1261.1)320.8 (96.3, 545.2)− 375.9 (− 841.4, 89.7)350.1 (12.0, 688.3)− 346.5 (− 895.1, 202.1)AUC over time when blood glucose \< 70 mg/dL is observed, mg/dL min43.0 (− 50.3, 136.3)11.8 (− 7.6, 31.2)− 31.2 (− 105.8, 43.3)0− 43.0 (− 136.3, 50.3)00.4 (− 0.4, 1.1)0.4 (− 0.4, 1.1)00MAGE, mg/dL98.02 (71.32, 124.73)69.60 (51.35, 87.85)− 28.42 (− 50.55, − 6.29)73.76 (59.63, 87.89)− 24.26 (− 44.71, − 3.82)114.91 (91.67, 138.14)65.75 (49.34, 82.16)− 47.25 (− 77.78, − 16.71)72.87 (54.80, 90.94)− 41.38 (− 66.75, − 16.01)Mean 24-h blood glucose, mg/dL145.65 (135.04, 156.27)137.52 (126.26, 148.77)− 8.14 (− 20.37, 4.09)137.19 (129.12, 145.26)− 8.46 (− 21.29, 4.37)161.01 (150.42, 171.61)144.24 (134.89, 153.59)− 16.77 (− 23.33, − 10.21)146.08 (136.65, 155.51)− 14.94 (− 21.97, − 7.90)Mean daytime blood glucose, mg/dL156.54 (144.85, 168.23)145.45 (132.36, 158.55)− 11.08 (− 25.75, 3.58)143.64 (134.43, 152.85)− 12.90 (− 26.16, 0.36)169.34 (158.93, 179.75)148.96 (139.77, 158.16)− 20.38 (− 28.27, − 12.48)149.56 (140.28, 158.85)− 19.78 (− 28.28, − 11.27)Mean nocturnal blood glucose, mg/dL120.87 (109.44, 132.30)118.22 (106.95, 129.48)− 2.65 (− 17.20, 11.89)121.93 (113.24, 130.63)1.06 (− 13.04, 15.16)143.29 (126.76, 159.81)132.60 (119.37, 145.83)− 10.69 (− 23.02, 1.64)137.33 (123.63, 151.03)− 5.96 (− 17.16, 5.24)AUC of blood glucose, mg/dL min41,947.9 (38,891.1, 45,004.7)39,607.5 (36,365.2, 42,849.8)− 2340.4 (− 5859.6, 1178.8)39,509.4 (37,182.9, 41,835.9)− 2438.5 (− 6134.2, 1257.1)46,372.7 (43,322.7, 49,422.7)41,543.8 (38,851.3, 44,236.3)− 4828.9 (− 6716.3, − 2941.6)42,069.8 (39,354.8, 44,784.7)− 4302.9 (− 6327.4, − 2278.5)Mean observed values displayed for baseline, day 22, and day 28. Values in parentheses refer to 95% CI for the mean*AUC* area under the glucose concentration--time curve, *CI* confidence interval, *MAGE* mean amplitude glycemic excursions

Additional Efficacy Endpoints {#Sec11}
-----------------------------

Changes in other glycemic parameters from baseline to day 21 and day 29 are shown in Table [3](#Tab3){ref-type="table"}. Plasma DPP4 inhibition rate at day 21 and day 29 are shown in Fig. [4](#Fig4){ref-type="fig"}. A reduction in glycoalbumin, fasting blood glucose, fasting glucagon, and plasma DPP4 activity, and an increase in the observed values of 1,5-AG, fasting GLP-1, and fasting GIP were seen at day 21 and day 29 in both groups compared with baseline (Table [3](#Tab3){ref-type="table"}).Table 3Other secondary efficacy endpoints: mean observed value and mean change from baseline in glycemic parametersTrelagliptin 100 mgAlogliptin 25 mgBaselineDay 21Change from baselineDay 29Change from baselineBaselineDay 21Change from baselineDay 29Change from baselineGlycoalbumin,  %17.77 (16.48, 19.06)17.07 (15.69, 18.45)− 0.7 (− 1.45, 0.05)16.59 (15.38, 17.81)− 1.18 (− 1.91, − 0.44)19.13 (17.96, 20.30)18.21 (16.94, 19.47)− 0.92 (− 1.39, − 0.46)17.84 (16.78, 18.89)− 1.29 (− 1.78, − 0.80)1,5-AG, μg/mL8.36 (5.06, 11.66)10.40 (6.44, 14.36)2.04 (0.99, 3.09)10.68 (6.90, 14.46)2.32 (1.24, 3.40)7.86 (5.82, 9.89)10.06 (7.78, 12.35)2.21 (1.60, 2.82)10.42 (8.17, 12.67)2.56 (1.83, 3.30)Fasting blood glucose, mg/dL144 (133.4, 154.6)137.2 (117.5, 156.9)− 6.8 (− 20.3, 6.8)130.4 (118.1, 142.6)− 13.6 (− 21.2, − 6.0)145.5 (134.4, 156.6)135.4 (127.9, 142.8)− 10.1 (− 19.1, − 1.2)130.5 (122.2, 138.8)− 15 (− 25.0, − 5.0)Fasting glucagon, pg/mL84.2 (73.5, 94.8)79.5 (69.8, 89.1)− 4.7 (− 12.5, 3.2)78.2 (69.2, 87.3)− 5.9 (− 14.0, 2.1)80.6 (68.8, 92.5)78.6 (67.6, 89.7)− 2.0 (− 11.4, 7.4)80.6 (65.2, 96.0)− 0.1 (− 10.8, 10.6)Fasting GLP-1, pmol/L0.78 (0.29, 1.27)2.53 (1.35, 3.71)1.75 (0.69, 2.81)1.76 (0.71, 2.81)0.98 (− 0.20, 2.16)1.14 (0.38, 1.90)4.08 (1.55, 6.61)2.94 (0.54, 5.35)4.15 (2.76, 5.54)3.01 (1.88, 4.13)Fasting GIP, pmol/L3.78 (2.40, 5.15)10.20 (5.94, 14.46)6.42 (2.91, 9.93)8.21 (3.32, 13.10)4.43 (0.23, 8.64)5.40 (3.79, 7.02)13.05 (10.02, 16.08)7.65 (4.70, 10.59)21.16 (7.83, 34.48)15.75 (3.18, 28.32)DPP4 activity, nmol/min/mL11.06 (9.53, 12.6)1.91 (1.32, 2.45)− 9.15 (− 10.52, − 7.79)3.39 (2.09, 4.68)− 7.68 (− 9.44, − 5.91)10.93 (8.86, 13.00)1.55 (1.19, 1.92)− 9.37 (− 11.33, − 7.42)1.79 (1.45, 2.13)− 9.14 (− 11.00, − 7.27)DPP4 inhibition rate, %NA82.64 (78.24, 87.04)NA69.00 (57.80, 80.19)NANA83.28 (75.64, 90.93)NA81.63 (75.46, 87.80)NAMean observed values displayed for baseline, day 21 and day 29. Values in parentheses refer to 95% CI for the mean*1,5*-*AG* 1,5-anhydroglucitol, *CI* confidence interval, *DPP4* dipeptidyl peptidase 4, *GIP* glucose-dependent insulinotropic polypeptide, *GLP*-*1* glucagon-like peptide 1, *NA* not applicableFig. 4Inhibition rate of plasma DPP4. DPP4 dipeptidyl peptidase 4, SD standard deviation

The frequency distributions of glucose values obtained from CGM appeared to shift toward lower glucose values from day 22 to day 28 in both groups, compared with baseline (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Frequency distributions of glucose values obtained from CGM. CGM continuous glucose monitoring

Safety {#Sec12}
------

One patient (7.7%) receiving once-weekly trelagliptin and two patients (14.3%) receiving once-daily alogliptin experienced TEAEs. One patient in the trelagliptin group experienced dizziness. In the alogliptin group, one patient experienced gastric mucosal lesion, feeling abnormal, and viral upper respiratory tract infection, and one patient experienced eczema. All TEAEs were mild in intensity, and no drug-related TEAEs were reported. No deaths, no serious TEAEs, or no serious TEAEs leading to drug discontinuation were reported in the study.

Discussion {#Sec13}
==========

GV is an important physiological phenomenon in patients with T2DM, which contributes not only to increased mean blood glucose values but also to the development of complications in chronic diabetes \[[@CR3]\]. There is evidence to suggest that tighter HbA1c control alone is insufficient for preventing diabetes complications, in particular cardiovascular events caused by long-term high GV \[[@CR20], [@CR21]\]. GV is therefore an important consideration in the management of blood glucose \[[@CR22]\]. It has been reported that DPP4 inhibitors have the potential to improve glycemic control and to reduce glucose fluctuations, by increasing active serum GLP-1 and GIP concentrations via glucose-dependent insulin secretion \[[@CR23], [@CR24]\]. Indeed, the long-term effect of once-daily alogliptin on glycemic control in Japanese patients with T2DM has been investigated, demonstrating a significant reduction in HbA1c (*p* = 0.0001) over 3.5 years \[[@CR25]\]. Trelagliptin administered once weekly is also efficacious \[[@CR18]\], is well-tolerated as a long-term mono- and combination therapy treatment option \[[@CR26]\], and is non-inferior to once-daily alogliptin \[[@CR18]\]. However, the effect of oral hypoglycemic agents, including once-weekly trelagliptin 100 mg and once-daily alogliptin 25 mg, on GV in patients with T2DM has not been investigated previously with regard to the frequency of administration.

In the present study, the administration of trelagliptin 100 mg once weekly or alogliptin 25 mg once daily decreased blood glucose levels and reduced GV to a similar extent in patients with T2DM, as measured by changes in SD of 24-h blood glucose and MAGE. Notably, this effect was maintained for 1 week after trelagliptin administration. During periods of high blood glucose (at least 180 mg/dL), postprandial and 24-h data obtained by CGM showed that both trelagliptin and alogliptin suppressed hyperglycemia. Again, this effect was maintained for up to 8 days after administration of once-weekly trelagliptin. We also quantitatively demonstrated that the risk of hypoglycemia was low in patients treated with trelagliptin or alogliptin, which is consistent with a previous report of DPP4 inhibitors and hypoglycemia \[[@CR15], [@CR27]\].

Inhibition of plasma DPP4 activity was maintained from day 21 to 29, with a mean DPP4 inhibition rate at day 21 and day 29 of 82.64% and 69.00%, respectively, in the trelagliptin group, and 83.28% and 81.63%, respectively, in the alogliptin group. Although the day 29 DPP4 inhibition rate was numerically lower with trelagliptin than with alogliptin, it should be noted that the rate with trelagliptin was measured 9 days after the final dose; this was comparable to the result of a phase 2 study that reported a DPP4 inhibition rate of 77.4% with once-weekly trelagliptin, 7 days after the final dose \[[@CR28]\]. Overall, these data support the current dosing frequencies of trelagliptin once weekly and alogliptin once daily.

By inhibiting DPP4 activity, trelagliptin and alogliptin increase plasma levels of the intact, active forms of GLP-1 and GIP. The glucose-dependent insulinotropic effects of both GLP-1 and GIP, as well as the glucagonostatic effect of GLP-1, are thought to underlie the therapeutic efficacy of trelagliptin and alogliptin. In the present study, a decrease in 3-h postprandial AUC after each meal was observed at day 22 and day 29 compared with baseline, and AUC at blood glucose levels less than 70 mg/dL was 0 at day 29 in both groups. These results indicate glucose-dependent insulinotropic effects of trelagliptin and alogliptin, and support their effects on reducing blood glucose without inducing hypoglycemia. Currently, it is unknown whether DPP4 inhibitory activity measured in the blood is similar to that in cells within the intestinal tract and periphery of the pancreas, and this warrants further investigation.

Both trelagliptin 100 mg and alogliptin 25 mg have been shown previously to have favorable safety profiles \[[@CR18], [@CR26], [@CR28]\] and, importantly, no new safety signals were identified in this study. Of note, Inagaki et al. reported that switching from once-daily sitagliptin to once-weekly trelagliptin in patients with T2DM and stable glycemic control in combination with diet and exercise therapy did not result in major changes in HbA1c and fasting plasma glucose \[[@CR29]\]. Safety and tolerability profiles remained favorable and there were no deaths, serious adverse events, or cases of hypoglycemia \[[@CR29]\]. The selection between trelagliptin and a once-daily DPP4 inhibitor will depend on the treatment policy of the physician, quality of life of the patient, and the patient's lifestyle and treatment preferences. For patients continuing long-term treatment, a once-weekly DPP4 inhibitor may be preferable for reducing the number of treatment visits, while delivering a stable and prolonged glucose-lowering effect that is comparable to that of a once-daily DPP4 inhibitor.

It has been suggested that DPP4 inhibitors may have a protective effect on pancreatic beta-cells by elongating the telomere length \[[@CR30]\]. It has also been reported that enhancement of the GLP-1 receptor signaling enhances beta-cell function, proliferation, and regeneration, and diminishes beta-cell apoptosis \[[@CR31]\]. Such protection may be continued and reinforced with long-term continued use of trelagliptin or alogliptin.

This study has several limitations. One limitation was the small number of enrolled patients. This was mainly due to the challenges of obtaining informed consent from patients with T2DM, based on the study design using CGM. CGM has been available through health insurance in Japan since 2009; however, patients are sometimes hesitant to use it because of the stress caused by insertion and removal of the CGM sensor, as well as the restriction of patients' activities during monitoring \[[@CR32]\]. CGM at baseline was therefore of a short duration to avoid inconvenience to the patients. An additional limitation could be the imbalance in CGM glucose values between treatment groups at baseline, although eligible patients were randomized 1:1 to receive either trelagliptin 100 mg or alogliptin 25 mg stratified by baseline HbA1c and age. Further studies enrolling larger patient populations are warranted. In addition, further investigation of the mode of action of once-weekly and once-daily DPP4 inhibitors may help us to better understand the effect of treatment frequency on GV in patients with T2DM.

Conclusions {#Sec14}
===========

Despite the different dosing frequencies, once-weekly trelagliptin and once-daily alogliptin improved glycemic control and reduced GV without inducing hypoglycemia.
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